Trial Profile
A Multiple Dose, Randomised, Double-blind, Placebo Controlled, 2 Period Crossover Clinical Trial to Assess the Effect of Aclidinium Bromide 400 μg BID on Exercise Endurance in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Almirall S.A.
- 11 Sep 2013 Primary endpoint 'Exercise-time' has been met according to results presented at the 23rd Annual Congress of the European Respiratory Society.
- 11 Sep 2013 Primary endpoint 'Endurance' has been met according to results presented at the 23rd Annual Congress of the European Respiratory Society.
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.